AdvaMed Statement on President’s Reciprocal Tariff Pause
WASHINGTON – Today AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker:
“We are encouraged by the President’s announcement of a 90-day pause on reciprocal tariffs. This is an important decision that restores some short-term certainty to global markets, including the American medtech industry, which is number one globally.
“Moving forward, we will spend the next 90 days working with the President and his senior team to ensure the unique role of the medtech industry is protected, with the hope that the ultimate outcome is ‘zero for zero’ tariffs on medtech with all key trading partners.”
Related Reading
Blog / Global & Trade / Government & Legislative Affairs / Regulatory Affairs / Tariffs
Medtech is Essential: Industry Supports Call for Tariff Flexibility
May 29, 2025
AdvaMed President and CEO Scott Whitaker testified before the U.S. Senate Finance Committee, bringing attention to the pressing issue of how tariffs could impact the medtech industry and, most importantly, the patients who depend on it.
Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs
URGENT: Court Ruling on Tariffs — Implications for Medtech
Now On Demand!
Emergency Briefing on Court Ruling on Tariffs and Its Impact on Medtech. Now On Demand!
News / Business Development / Government & Legislative Affairs / Small Business
AdvaMed Welcomes Introduction of American Innovation and Jobs Act
May 22, 2025
WASHINGTON—AdvaMed, the Medtech Association, welcomed introduction of the bipartisan Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by U.S. Sens. Shelley Moore Capito (R-W.Va.) and Jeanne Shaheen (D-N.H.) and U.S. Reps. Kevin Hern (R-Okla.) and Mike Thompson (D-Calif.). The bill provides for Medicare and Medicaid coverage of evidence-based software applications used to prevent, manage, or treat medical conditions.
News / Coverage & Payment / Digital Health / Government & Legislative Affairs
AdvaMed Welcomes Introduction of Access to Prescription Digital Therapeutics Act
May 22, 2025
WASHINGTON—AdvaMed, the Medtech Association, welcomed introduction of the bipartisan Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by U.S. Sens. Shelley Moore Capito (R-W.Va.) and Jeanne Shaheen (D-N.H.) and U.S. Reps. Kevin Hern (R-Okla.) and Mike Thompson (D-Calif.). The bill provides for Medicare and Medicaid coverage of evidence-based software applications used to prevent, manage, or treat medical conditions.
News / Coverage & Payment / Government & Legislative Affairs
AdvaMed Welcomes the Re-Introduction of the Ensuring Patient Access to Critical Breakthrough Products Act
May 22, 2025
Washington, D.C.–AdvaMed President and CEO Scott Whitaker released the following statement upon re-introduction of bipartisan legislation aimed at accelerating Medicare coverage for breakthrough medtech and diagnostics. The Ensuring Patient Access to Critical Breakthrough Products Act, introduced by Senators Todd Young (R-Ind.) and Alex Padilla (D-Calif.), allows Medicare beneficiaries with life-threatening or debilitating diseases or conditions access to groundbreaking medical innovations, designated as breakthrough devices to treat unmet needs and already authorized by the FDA.
Blog / Government & Legislative Affairs / Regulatory Affairs
Orthogonal, Kwame Ulmer on the Value of AdvaMed Membership
May 20, 2025
At AdvaMed, we’re proud to be recognized for our work on behalf of the medtech community – and we’re especially grateful when that recognition comes from respected voices like Kwame Ulmer of MedTech Impact Partners and our colleagues at Orthogonal.
News / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Tariffs
Swiss Medtech and AdvaMed Call for Zero for Zero Tariffs and Recognition of FDA Approvals and Clearances
May 20, 2025
Bern/Washington – Swiss Medtech, the leading trade association for medical technology companies in Switzerland, and AdvaMed, the U.S. Medtech Association and the world’s largest organization representing medtech innovators, are jointly calling for reciprocal “zero for zero” tariffs between the two countries.
Resource / Emerging Policy Response Resources / Government & Legislative Affairs
Executive Overview_Kennedy v. Braidwood Management, Inc.
May 15, 2025
The U.S. Supreme Court is reviewing Braidwood Management v. Becerra, a high-stakes case challenging the authority of the U.S. Preventive Services Task Force (USPSTF) under the Affordable Care Act. At the heart of the case is whether USPSTF recommendations—used to mandate insurance coverage for preventive services—are constitutionally valid.